PLB-1001 CAS#: 1440964-89-5; ChemWhat Code: 1417548
Identification
Patent Information | ||
Patent ID | Title | Publication Date |
WO2022/226168 | DIAGNOSTIC AND TREATMENT OF CANCER USING C-MET INHIBITOR | 2022 |
WO2021/222045 | NOVEL PHARMACEUTICAL FORMULATION FOR C-MET INHIBITOR | 2021 |
WO2019/161320 | CANCER TREATMENT USING COMBINATION OF NEUTROPHIL MODULATOR WITH MODULATOR OF IMMUNE CHECKPOINT | 2019 |
WO2014/32498 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | 2014 |
Physical Data
Melting Point, °C |
203 |
221.16 |
Spectra
Route of Synthesis (ROS)
Conditions | Yield |
With methanesulfonic acid; 1-methoxy-2-propanol In methanol at 90℃; for 16h; Experimental Procedure 44 Example 44 : 6-(l-Cyclopropyl-lH-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-inethyl-(2H- indazol-5-yl)methyl)-[l,2,4]triazolo[4,3-b]pyridazine General procedure: Example 44 : 6-(l-Cyclopropyl-lH-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-inethyl-(2H- indazol-5-yl)methyl)-[l,2,4]triazolo[4,3-b]pyridazine To a 100 n L round bottom flask is added l-methoxy-2-propanol (15 n L), methyl sulfonic acid (0.898 g, 9.4 mmol), 2,2-difluoro-2-(6-fluoro-2-methyl-2H-indazol-5-yl) acetohydrazide (2.01 g, 7.8 mmol), and 3-chloro-6-(l-cyclopropyl-lH-pyrazol-4-yl) pyridazine (1.81 g, 8.2 mmol). The reaction mixture is stirred at 90 °C for 16 hr. After removal of solvent, the residue is purified on a silica gel flash chromatography with methanol/dichloromethane (1 :20) to yield a light yellow solid (1.32 g, 40% yield). (MS: [M+l] 425) | 40% |
Safety and Hazards
GHS Hazard Statements | Not Classified |
Other Data
HS Code | |
Storage | Store at -20°C and away from light |
Shelf Life | 2 years |
Market Price |
Druglikeness | |
Lipinski rules component | |
Molecular Weight | 424.388 |
logP | 5.934 |
HBA | 8 |
HBD | 0 |
Matching Lipinski Rules | 3 |
Veber rules component | |
Polar Surface Area (PSA) | 78.72 |
Rotatable Bond (RotB) | 4 |
Matching Veber Rules | 2 |
Use Pattern |
PLB-1001 CAS#: 1440964-89-5 is a receptor tyrosine kinase inhibitor targeting the cell-mesenchymal-epithelial transition factor (c-MET), capable of inhibiting the proliferation of tumor cells with elevated c-MET expression. This drug can penetrate the blood-brain barrier and has been registered for 8 clinical trials domestically, with indications including non-small cell lung cancer (NSCLC), gliomas, and more. |
Buy Reagent | |
No reagent supplier? | Send quick inquiry to ChemWhat |
Want to be listed here as a reagent supplier? (Paid service) | Click here to contact ChemWhat |
Approved Manufacturers | |
Caming Pharmaceutical Limited | http://www.caming.com/ |
Want to be listed as an approved manufacturer (Requires approvement)? | Please download and fill out this form and send back to approved-manufacturers@chemwhat.com |
Contact Us for Other Help | |
Contact us for other information or services | Click here to contact ChemWhat |